Bristol Myers Squibb reported that its pivotal multiple myeloma CAR T trial using a GPRC5D-directed construct hit its primary endpoint, extending the company’s push to challenge Johnson & Johnson in the post-BCMA space. The news points to continued momentum across BMS’s cell-therapy strategy beyond BCMA targets, as companies race to establish positioning by line of therapy and patient phenotype. Coverage emphasized the result moves the program forward on clinical efficacy criteria. This comes as the myeloma CAR T competitive landscape broadens into multiple targets and differentiated treatment sequences, with regulators reviewing more complex trial designs and manufacturing considerations. Taken alongside earlier QUINTESSENTIAL differentiation news, the GPRC5D update reinforces BMS’s intent to build a CAR T franchise with distinct clinical niches.